DualityBio has updated its Phase I/II study results for DB-1311, a B7H3-targeting antibody-drug conjugate being developed to treat metastatic castration-resistant prostate cancer. The study showed promising results, with data indicating the potential effectiveness of the treatment in patients with post-pluvicto disease globally. A global Phase III clinical trial has also been initiated based on the study’s findings, targeting taxane-naïve mCRPC patients.
Source: https://insights.citeline.com/scrip/r-and-d/clinical-trials/in-brief-strong-results-advance-dualitybiobiontechs-b7h3-adc-into-phase-iii-crpc-trial-ULXY2WH6P5ETHILZWBS23PN4CY